TRACON Pharmaceuticals Inc., a well-known player in the biopharmaceutical sector, has recently garnered attention for its exceptional after-hours showing in the US stock market. This
TRACON Pharmaceuticals, Inc. (TCON) is a leading late-clinical company focused on the development and marketing of cancer therapeutics along with treatment for macular degeneration and
Tracon Pharmaceuticals, Inc. (TCON) is a leading clinical stage company engaged in the development and commercialization of oncology related therapies. The company also develops treatment
TRACON Pharmaceuticals, Inc. (TCON) stock prices were down 4.27% as of the market closing on July 21st, 2021, bringing the price per share down to
TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced today that it has received Orphan Drug Designation for TRC102 for the treatment of patients suffering from malignant
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.